BioLineRx Ltd. Stock News

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided

BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2022 Earnings Conference Call March 22, 2023 10:00 AM ET Company Participants John Lacey - Investor Relations Philip Serlin - Chief Executive Officer Mali Zeevi - Chie

BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2022 Earnings Conference Call November 15, 2022 10:00 AM ET Company Participants John Lacey - IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial O

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2022 Earnings Conference Call August 16, 2022 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi -

BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2022 Earnings Conference Call May 11, 2022 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - CEO Mali Zeevi - CFO Conference Call Pa

BioLineRx Earnings Beat, Revenue Inline In Q1

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q4 2021 Results - Earnings Call Transcript

biolinerx press release (BLRX): FY GAAP EPS of -$0.04 beats by $0.42.CEO comment: "With over $57 million in cash, we believe we are well financed to extract maximum value…

Companies Reporting Before The Bell • Ideanomics (NASDAQ: IDEX ) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena International (NASDAQ: TEDU ) is likely to report earnings for its fourth quarter. • Jabil (NYSE: JBL ) is expected to report quarterly earnings at $1.47 per share on revenue of $7.43 billion. • ImmunoPrecise Antibodies (NASDAQ: IPA ) is expected to report quarterly loss at $0.13 per share on revenue of $4.14 million. • BRC (NYSE: BRCC ) is projected to report quarterly loss at $0.02 per share on revenue of $68.90 million. • BioLine Rx (NASDAQ: BLRX ) is projected to report earnings for its fourth quarter. • Lands'' End (NASDAQ: LE ) is estimated to report quarterly earnings at $0.31 per share on revenue of $567.68 million. • DouYu International Hldgs (NASDAQ: DOYU ) is estimated to report quarterly loss at $0.07 per share on revenue of $354.87 million. • Ampco-Pittsburgh (NYSE: AP ) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ: RMBL ) is likely to report quarterly earnings at $0.43 per share on revenue of $375.23 million. • Membership Collective (NYSE: MCG ) is likely to report quarterly loss at $0.16 per share on revenue of $187.88 million. • Shoe Carnival (NASDAQ: SCVL ) is expected to report quarterly earnings at $0.44 per share on revenue of $280.42 million. • Arcos Dorados Holdings (NYSE: ARCO ) is estimated to report quarterly earnings at $0.16 per share on revenue of $750.54 million. • Telos (NASDAQ: TLS ) is projected to report quarterly earnings at $0.11 per share on revenue of $76.02 million. • …

Announcing additional data from a follow-on study based on its Phase 3 GENESIS trial, BioLineRx <> touted the economic benefits of motixafortide, its experimental agent for stem…

Penny stocks to watch after news today The post 5 Hot Penny Stocks To Watch Today Trading Higher After News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Bioline Rx Ltd - ADR (BLRX) shares closed today at 2.0% above its 52 week low of $2.05, giving the company a market cap of $102M. The stock is currently down 15.1% year-to-date, down 12.7% over the past 12 months, and down 84.7% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 29.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 125.2% The company's stock price performance over the past 12 months lags the peer average by 64.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 116,700 shares, a decrease of 36.7% from the November 15th total of 184,500 shares. Based on an average daily trading volume, of 368,500 shares, the days-to-cover ratio is []

TEL AVIV, Israel, Dec. 17, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today provided updates from an oral presentation delivered by Dr. Zachary Crees from the Washington University School of